Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
Pfizer stock has declined 27.7% over the past 5 years, yet the current valuation checks and market multiples now point to a picture that looks closer to fair than clearly cheap or expensive.
The 5-year return of 27.7% in the red means long-term shareholders are still under water, which can make today’s pricing feel more attractive than it may actually be on fundamentals.
Recent positive trial results for LITFULO in nonsegmental vitiligo and regulatory progress for vaccines and oncology treatments can support expectations for future cash flows, while political pressure on drug pricing and potential tariffs on generics remain a key risk to how investors value Pfizer.
With a value score of 4 out of 6, Pfizer screens as a mixed picture rather than a clear bargain or clear overvaluation on the broader checks.
The issue now is whether Pfizer’s current share price already reflects this mix of pipeline progress and policy risk, or if there is still a margin of safety for new investors.
Find out why Pfizer’s 13.9% return over the last year is lagging behind its peers.
Is Pfizer Fairly Priced on Earnings?
The P/E ratio is a useful lens for Pfizer because earnings power is central to how investors typically view large pharmaceutical stocks. Pfizer currently trades on a P/E of 19.1x, which is higher than the pharmaceuticals industry average of 14.9x but sits well below the peer group average of 34.9x. That places Pfizer in the middle of the pack, neither clearly cheap nor clearly expensive compared with similar large drug companies.
The Fair Ratio model, which adjusts for Pfizer’s size, margins, sector and risk profile, points to a P/E of 19.7x as a reasonable anchor. The current 19.1x level is very close to that figure, so the market price already appears to reflect expectations around its pipeline and ongoing policy risks. Despite the recent positive readouts and regulatory progress, including the new Phase 3 results for LITFULO, the P/E still prices Pfizer roughly in line with what this framework suggests.
On the P/E multiple, Pfizer stock currently looks approximately fairly valued.
See what the numbers say about this price — find out in our valuation breakdown.
The Pfizer Narrative: What Would Justify Today’s Price?
Simply Wall St Narratives for Pfizer pick up where this valuation puzzle leaves off and spell out what would need to happen to Pfizer’s growth, margins and earnings for the stock to be worth clearly more or clearly less than today’s price. Rather than relying on a single multiple or model output, each narrative lays out the key assumptions behind its view of fair value so you can compare those with Pfizer’s actual results as they come through. These appear on Simply Wall St’s Community page and give you a structured way to test your own expectations against the different paths investors are considering for the company.